Recent advances in atezolizumab-based programmed death-ligand 1 (PD-L1) blockade therapy for breast cancer

Area of Science:

• Oncology
• Immunotherapy
• Pharmacology

Background:

• Breast cancer is a leading cause of cancer death in women, with advanced stages remaining incurable.
• Emerging immunotherapies, including immune checkpoint inhibitors (ICIs), are being investigated for metastatic breast cancer.
• Targeting immune checkpoints like PD-1/PD-L1 is a key strategy, particularly for triple-negative breast cancer (TNBC).

Purpose of the Study:

• To review the clinical efficacy of atezolizumab in breast cancer treatment.
• To discuss the role of atezolizumab in targeting PD-L1 for immunotherapy.
• To summarize the potential immune-related adverse events (irAEs) associated with atezolizumab therapy.

Main Methods:

• Review of clinical trial data, focusing on the IMpassion130 trial.
• Analysis of atezolizumab's mechanism of action as a monoclonal antibody targeting PD-L1.
• Summary of approved treatment combinations involving atezolizumab.

Main Results:

• Atezolizumab, in combination with nab-paclitaxel, is approved for unresectable locally advanced or metastatic PD-L1-positive TNBC.
• Targeting PD-L1 with atezolizumab enhances T-cell responses against tumors.
• The IMpassion130 trial demonstrated significant outcomes leading to this approval.

Conclusions:

• Atezolizumab represents a significant advancement in breast cancer immunotherapy, especially for TNBC.
• The combination therapy offers a new option for patients with advanced, metastatic PD-L1-positive TNBC.
• Further understanding of irAEs is important for managing patients on atezolizumab therapy.